

المؤتمر السنوي الدولي للجمعية المصرية
INTERNATIONAL CONGRESS OF THE

EGYPTIAN OPHTHALMOLOGICAL SOCIETY


EOS 2023



Dynamic Progression of iRORA and cRORA Lesions in

AMD: Post Hoc Analysis of TREX-AMD Trial

Mohamed Salah Helal, MSc. FEBO.



1

Disclosure


The author has no financial interest
in the matter of this presentation



2

Age Related Macular Degeneration (ARMD)

- One of the most common causes of visual loss worldwide
- Dry type & wet type (CNV)
- Both types may be associated with retinal atrophy (RORA)
- Classification of Atrophy Meetings (CAM) classification (iRORA & cRORA)



Nizar S. Abdelfattah, Maissy Al-Shelkh, Sean Pitetta, Ahmed Mousa, Srinivas R. Satta, Charles C. Wykoff, Charles C. Wykoff, Daniel E. Croft, David M. Brown, Rui Wang, John F. Payne, Lloyd Clark, Nizar Saleh Abdelfattah, Srinivas R. Satta, Matthew S. Benz, Eric Chen, Richard H. Fish, David L. Johnson, Rosa Y. Kim, James C. Major, Ronan E. O'Malley, Amy C. Scheffler, Ankooor R. Shah, Sushma K. Vance, John A. Wells, Tien P. Wong, Macular Atrophy in Neovascular Age-Related Macular Degeneration with Monthly versus Treat-and-Extend Ranibizumab: Findings from the TREX-AMD Trial, Ophthalmology, Volume 124, Issue 2, 2017, Pages 215-223, ISSN 0161-6420.



3

Aim of the Study


- To quantify incidence of iRORA and conversion rate of iRORA to cRORA in eyes treated with ranibizumab monthly or using a treat-and-extend (TREX) regimen for NVAMD or fellow control eyes



4

Methodology

- Sixty patients with unilateral treatment-naïve NVAMD randomized 1:2 to monthly or TREX ranibizumab were followed for 36 months.
- Atrophy was quantified with SDOCT guidance (Heidelberg SPECTRALIS® OCT) using CAM criteria for incomplete and complete RPE and outer retinal atrophy iRORA/cRORA.
- Atrophy was measured on FAF images using Region Finder (Heidelberg Engineering).



5

Results

- Baseline iRORA lesions are common in treatment-naïve eyes: monthly (n = 4), TREX (n = 21), and control fellow eyes (n = 8). Incidence rate of cRORA lesions in eyes with iRORA at baseline was 75% in the monthly group, 52.4% in TREX group, and 62.5% among controls. In eyes with no baseline iRORA, incidence rate of cRORA lesions was 25% (monthly), 43.5% (TREX), and 34.4% (control).
- **Ranibizumab did not show a statistically significant influence on new cRORA development or progression of iRORA to cRORA lesions.**



6

Take Home Message

- Macular atrophy can be associated with dry or wet AMD
- Follow up is recommended to detect early iRORA and its progression
- Ranibizumab injection has no significant effect on iRORA formation or progression of iRORA to cRORA

